History of thromboembolic or cerebrovascular events ? 6 months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboliXx_NEWLINE_xXHistory of arterial thrombotic or embolic events (within 6 months prior to study entry)Xx_NEWLINE_xXCerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months\r\n* Note: subjects with recent DVT who have been therapeutically coagulated for at least 6 weeks are eligibleXx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study registrationXx_NEWLINE_xXHistory of thromboembolic or cerebrovascular events ? 6 months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboli.Xx_NEWLINE_xXPatients will be excluded if any of the following are present, evidence of active bleeding, intratumoral hemorrhage, or bleeding diathesis; History (within 6 months prior to study enrollment) of arterial thromboembolic events, including transient ischemic attack (TIA) or cerebrovascular accident (CVA); history (within 6 months prior to study enrollment) of pulmonary embolism, deep venous thrombosis (DVT), or other venous thromboembolic event; history of clinically significant bleeding within 6 weeks prior to study enrollment.Xx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident, deep vein thrombosis or pulmonary embolus within 6 months of informed consentXx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment within 6 months of informed consentXx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment within 6 months of informed consentXx_NEWLINE_xXHistory of thromboembolic or cerebrovascular events within the last 6 months, including transient ischemic attack, cerebrovascular accident, deep vein thrombosis, or pulmonary embolismXx_NEWLINE_xXcerebrovascular accident, including transient ischemic attacks within the past 6 months.Xx_NEWLINE_xXNo history of cerebrovascular accident, transient ischemic attacks, central nervous system or brain metastasesXx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) or deep venous thrombosis (DVT) within 6 months of informed consent\r\n* Tumor or bland thrombus in hepatic vasculature is not a contraindication provided hepatic function criteria are metXx_NEWLINE_xXSignificant thrombotic or embolic events within 4 weeks prior to study day 1; significant thrombotic or embolic events include but are not limited to stroke or transient ischemic attack (TIA); catheter-related thrombosis is not a cause for exclusion; diagnosis of deep vein thrombosis or pulmonary embolism is allowed if it occurred > 4 weeks prior to study day 1 and the patient is asymptomatic and stable on anti-coagulation therapyXx_NEWLINE_xXSevere or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to enrollmentXx_NEWLINE_xXPatients with arterial thrombotic events, such as cerebrovascular accident or myocardial infarction, within 6 months of enrollmentXx_NEWLINE_xXFOR ALL PHASES (Ib AND II): Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before the start of study medicationXx_NEWLINE_xXHistory of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism, or untreated deep venous thrombosis (DVT) within the past 6 monthsXx_NEWLINE_xXSubjects diagnosed with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 3 months of start of study treatmentXx_NEWLINE_xXThrombotic or embolic events;Xx_NEWLINE_xXThrombotic, embolic, venous or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months of informed consentXx_NEWLINE_xXArterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), or venous pulmonary embolism within 6 months before the start of study treatment; venous thrombotic events such as deep vein thrombosis within 3 months before the start of study treatmentXx_NEWLINE_xXArterial thrombotic or embolic events such as cerebrovascular accident (including ischemic attacks) or hemoptysis within 6 months before the first dose of study drug.Xx_NEWLINE_xXThrombotic or embolic events such as a cerebrovascular accident including transient ischemic, attacks, deep vein thrombosis (DVT) within the past 6 monthsXx_NEWLINE_xXSevere or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomizationXx_NEWLINE_xXSORAFENIB\r\n* Major surgery, open biopsy, or significant traumatic injury within 30 days\r\n* Non-healing wound, ulcer, or bone fracture\r\n* Thrombotic or embolic venous or arterial events, such as cerebrovascular accident, including transient ischemic attacks, arterial thrombosis, deep vein thrombosis and pulmonary embolism within the past 6 months\r\n* Upper Extremity/Line associated DVTs which are adequately treated (line removed and/or patient anticoagulated) are eligible\r\n* Uncontrolled hypertension\r\n* Active bleeding during screening\r\n* Hypersensitivity to sorafenibXx_NEWLINE_xXSignificant thrombotic or embolic events within 3 months prior to study day 1; significant thrombotic or embolic events include but are not limited to stroke or transient ischemic attack (TIA); catheter-related thrombosis is not a cause for exclusion; diagnosis of deep vein thrombosis or pulmonary embolism is allowed if the patient is clinically stable and has completed or is on stable anti-coagulation therapyXx_NEWLINE_xXHave clinically significant heart disease as evidenced by severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomizationXx_NEWLINE_xXArterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months before enrollmentXx_NEWLINE_xXAny documented history of clinically identifiable thrombotic, embolic, venous, or arterial events such as cerebrovascular accident, transient ischemic attack, deep vein thrombosis, or pulmonary embolism within 6 months prior to initiating study treatment\r\n* Note: Patients with an asymptomatic catheter-related thrombus or a tumor-associated thrombus of locally-involved vessels or with incidental asymptomatic filling defects identified on imaging are not excludedXx_NEWLINE_xXHistory of thromboembolic or cerebrovascular events within the last 6 months, including transient ischemic attack, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism (applicable to combination part only).Xx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatmentXx_NEWLINE_xXAny documented history of thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident, transient ischemic attack, deep vein thrombosis, or pulmonary embolism within 6 months prior to initiating study treatment\r\n* Note: patients with a tumor-associated thrombus of locally-involved vessels should not be excluded from participating in the studyXx_NEWLINE_xXThrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 monthsXx_NEWLINE_xXCerebrovascular accident at any time in the past, transient ischemic attack, deep venous thrombosis or pulmonary embolism in the past 6 monthsXx_NEWLINE_xXArterial thrombotic or embolic events such as a myocardial infarction or cerebrovascular accident (including transient ischemic attacks) within the 6 months prior to initiation of treatment; incidental clinically insignificant embolic phenomena that do not require anti-coagulants are not excluded; also, tumor-associated thrombus of locally-involved vessels does not count as an exclusion criterionXx_NEWLINE_xXArterial thromboembolic or embolic events such as myocardial infarction, cerebrovascular accident, including transient ischemic attacks within 6 months prior to first study treatmentXx_NEWLINE_xXSorafenib\r\n* Major surgery, open biopsy, or significant traumatic injury within 30 days\r\n* Non-healing wound, ulcer, or bone fracture\r\n* Thrombotic or embolic venous or arterial events, such as cerebrovascular accident, including transient ischemic attacks, arterial thrombosis, deep vein thrombosis and pulmonary embolism within the past 6 months\r\n* Uncontrolled hypertension\r\n* Active bleeding during screening\r\n* Hypersensitivity to sorafenibXx_NEWLINE_xXHistory of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; note: subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligibleXx_NEWLINE_xXThrombolic or embolic events (except deep vein thrombosis [DVT] or pulmonary embolus) such as a cerebrovascular accident including transient ischemic attacks within the past 6 monthsXx_NEWLINE_xXHistory of any of the following:\r\n* Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 6 months of cycle 1 day 1, brain arteriovenous malformation, Schwannoma, meningioma, or other benign central nervous system [CNS] or meningeal disease which may require treatment with surgery or radiation therapy)\r\n* Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to first dose of study drug; venous thrombotic events within 6 months are permitted IF they are not attributed to prostate cancer (in the opinion of the treating physician)Xx_NEWLINE_xXArterial or venous thrombotic events or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before randomizationXx_NEWLINE_xXAny of the following within 6 months prior to randomization: Severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmiasXx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatmentXx_NEWLINE_xXSevere or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to registrationXx_NEWLINE_xXAny documented history of clinically significant thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident, transient ischemic attack, deep vein thrombosis, or pulmonary embolism necessitating therapeutic anticoagulation within 6 months prior to initiating study treatment; Note: Patients with a tumor-associated thrombus of locally-involved vessels should not be excluded from participating in the studyXx_NEWLINE_xXArterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before registrationXx_NEWLINE_xXPatients with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of the study registrationXx_NEWLINE_xXSignificant thrombotic or embolic events within 3 months prior to study day 1; significant thrombotic or embolic events include but are not limited to stroke or transient ischemic attack (TIA); catheter-related thrombosis is not a cause for exclusion; diagnosis of deep vein thrombosis or pulmonary embolism is allowed if it occurred > 3 months prior to study day 1 and the patient has completed or is on stable anti-coagulation therapyXx_NEWLINE_xXPatients with a history of thrombotic or embolic events within the last six months such as a cerebrovascular accident (including transient ischemic attacks), pulmonary embolismXx_NEWLINE_xXPatients with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks [TIAs]) within 6 months before randomizationXx_NEWLINE_xXHistory of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; Note: patients with recent DVT who have been treated with therapeutic anticoagulation agents for at least 6 weeks are eligible as long as their INR is stable and within inclusion criteria aboveXx_NEWLINE_xXAngina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, PTCA or CABG within the past 6 months. Deep venous thrombosis within 6 months, unless the patient is anti-coagulated without the use of warfarin for at least 2 weeks. In this situation, low molecular weight heparin is preferred.Xx_NEWLINE_xXHistory of cerebrovascular accident within the past 6 monthsXx_NEWLINE_xXArterial or venous thrombotic or embolic events such as cerebral vascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before randomization (except for adequately treated catheter-related venous thrombosis occurring within 6 months before randomization).Xx_NEWLINE_xXAngina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, PTCA or CABG within the past 6 months. Deep venous thrombosis within 6 months unless the patient is anticoagulated without the use of warfarin for at least 2 weeks. In this situation, low molecular weight heparin is preferred.Xx_NEWLINE_xXThrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 monthsXx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within 6 months of start of study treatment.Xx_NEWLINE_xXAny history of thrombotic cerebrovascular accident or other arterial thrombosisXx_NEWLINE_xXThrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 monthsXx_NEWLINE_xXHistory of thromboembolic or cerebrovascular events =< 6 months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboliXx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of study treatment startXx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of informed consentXx_NEWLINE_xXArterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism =< 6 months prior to randomizationXx_NEWLINE_xXSignificant thrombotic or embolic events within 4 weeks prior to study day 1; significant thrombotic or embolic events include but are not limited to stroke or transient ischemic attack (TIA); catheter-related thrombosis is not a cause for exclusion; diagnosis of deep vein thrombosis or pulmonary embolism is allowed if it occurred > 4 weeks prior to study day 1 and the patient is asymptomatic and stable on anti-coagulation therapyXx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism =< 6 months prior to registrationXx_NEWLINE_xXArterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months before start of study medication (except for adequately treated catheter-related venous thrombosis occurring more than 1 month before the start of study medication)Xx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of informed consentXx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatmentXx_NEWLINE_xXThrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 monthsXx_NEWLINE_xXHistory of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.Xx_NEWLINE_xXHistory of arterial thrombotic or embolic events (within 6 months prior to study entry)Xx_NEWLINE_xXHistory of arterial or embolic events (within 6 months prior to study entry)Xx_NEWLINE_xXHistory of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; Note: subjects with recent DVT who have been treated with therapeutic anticoagulating agents for at least 6 weeks prior to study treatment are eligibleXx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) within 6 months of informed consentXx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) within 6 months of informed consentXx_NEWLINE_xXHistory of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 monthsXx_NEWLINE_xXArterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before the start of study medication.Xx_NEWLINE_xXPatient must not have a history of cerebrovascular accident including transient ischemic attack within the past 6 months; patients with recent deep venous thrombosis or pulmonary embolism who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible as long as INR is stableXx_NEWLINE_xXHistory of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within 6 months of registration; note: subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks prior to registration and are fully anti-coagulated are eligibleXx_NEWLINE_xXCerebrovascular accident within prior 6 monthsXx_NEWLINE_xXHistory of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; Note: subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligibleXx_NEWLINE_xXHistory of cerebrovascular accident including transient ischemic attack, untreated deep venous thrombosis (DVT) or pulmonary embolism within the past 6 months; patients with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligibleXx_NEWLINE_xXHistory of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; note: subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible but must be monitored regularly for changes in relevant coagulation parameters as clinically indicated as well as any clinical bleeding episodesXx_NEWLINE_xXArterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), or pulmonary embolism within the 6 months before start of FOLFIRIXx_NEWLINE_xXThrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 monthsXx_NEWLINE_xXThrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months; hepatic portal vein thrombus is not considered an exclusion criterionXx_NEWLINE_xXNo history of cerebrovascular accident or transient ischemic attacksXx_NEWLINE_xXThrombotic or embolic events such as cerebrovascular accident, deep vein thrombosis or pulmonary embolism. History of transient ischemic attack is allowed.Xx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months of study registration.Xx_NEWLINE_xXArterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months before start of study medication (except for adequately treated catheter-related venous thrombosis occurring more than 1 month before the start of study medication).Xx_NEWLINE_xXArterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before start of study treatment. However, if a patient has recovered to ECOG performance status of ? 2 he/she may be enrolled provided that other eligibility criteria are metXx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatmentXx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatmentXx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism that have initiated within 6 months of start of study treatment; stable, persistent events under appropriate management diagnosed > 6 months prior to treatment are allowed at the discretion of the investigatorXx_NEWLINE_xXArterial or venous thrombotic or embolic eventsXx_NEWLINE_xXHistory of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism, or untreated deep venous thrombosis (DVT) within the past 6 months; subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligibleXx_NEWLINE_xXHave had arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within 6 months prior to the initiation of study treatment.Xx_NEWLINE_xXHistory of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.Xx_NEWLINE_xXThromboembolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 monthsXx_NEWLINE_xXThrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 monthsXx_NEWLINE_xXNo history of cerebrovascular accident or transient ischemic attacks within the past 6 months from registrationXx_NEWLINE_xXHistory of arterial or venous thrombotic/embolic events =< 12 months prior to registrationXx_NEWLINE_xXArterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before the start of study medicationXx_NEWLINE_xXCerebrovascular accident or pulmonary embolus within 3 months of randomization.Xx_NEWLINE_xXKnown history of cerebrovascular accident in the past 6 months.Xx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months of informed consent; Note: subjects with recent deep vein thrombosis (DVT) who have been treated with therapeutic anticoagulating agents for at least 6 weeks prior to study treatment are eligibleXx_NEWLINE_xXThrombolytic, embolic, venous, or arterial events such as cerebrovascular accident including transient ischemic attacks within the past 6 monthsXx_NEWLINE_xXHistory of cerebrovascular accident including transient ischemic attack, pulmonary embolism, or untreated deep venous thrombosis within the past 6 months.Xx_NEWLINE_xXThrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 monthsXx_NEWLINE_xXNo history of cerebrovascular accident or transient ischemic attacks within the past 6 monthsXx_NEWLINE_xXThrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 monthsXx_NEWLINE_xXThrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 monthsXx_NEWLINE_xXThrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 monthsXx_NEWLINE_xXHistory of a thrombotic or thromboembolic event (arterial or venous) in the past 6 monthsXx_NEWLINE_xXHistory of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; note: subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligibleXx_NEWLINE_xXHave had arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within 3 months prior to the initiation of study treatmentXx_NEWLINE_xXSubjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment within 6 months of informed consentXx_NEWLINE_xXPatients with a history of a prior symptomatic venous thrombotic event, such as deep venous thrombosis (DVT) or pulmonary embolism and symptomatic arterial thrombotic events such as myocardial infarction, ischemic cerebral vascular accident or transient ischemic attack will be ineligible if they have not tolerated anticoagulation therapy; if patients remain on anticoagulation, or have completed the prescribed course of anticoagulation, they will be eligible for enrollment; a venous thrombotic event associated with a central venous catheter will not make the patient ineligibleXx_NEWLINE_xXHas an unstable neurological disease (e.g. cerebrovascular accident [including transient ischemic attacks (TIAs)]) within the 3 months before signing of informed consentXx_NEWLINE_xXPatient must not have history of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months\r\n* Note: subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligibleXx_NEWLINE_xXCerebrovascular accident or transient ischemia.Xx_NEWLINE_xX